Arcus Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2016
Net Income	-231	-307	-267	53	-123	-84.71	Upgrade
Depreciation & Amortization	17	16	14	7	4	3.58	Upgrade
Share-Based Compensation	74	73	65	55	22	8.98	Upgrade
Other Operating Activities	-70	-88	626	-371	208	-1.31	Upgrade
Operating Cash Flow	-210	-306	438	-256	111	-73.46	Upgrade
Capital Expenditures	-25	-24	-6	-26	-3	-1.93	Upgrade
Acquisitions	0	0	-3	0	0	0	Upgrade
Change in Investments	-79	218	-404	22	-431	61.14	Upgrade
Investing Cash Flow	-104	194	-413	-4	-434	59.21	Upgrade
Share Issuance / Repurchase	261	33	23	232	439	1.12	Upgrade
Other Financing Activities	-	-	10	5	-	-	Upgrade
Financing Cash Flow	261	33	33	237	439	1.12	Upgrade
Net Cash Flow	-53	-79	58	-23	116	-13.13	Upgrade
Free Cash Flow	-235	-330	432	-282	108	-75.39	Upgrade
Free Cash Flow Margin	-99.16%	-282.05%	385.71%	-73.63%	138.46%	-502.58%	Upgrade
Free Cash Flow Per Share	-2.73	-4.46	6.00	-4.07	1.97	-1.72	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).